Background: This monocentric study evaluates the activity and tolerability of docetaxel (Taxotere), cisplatin and 5-fluorouracil (5-FU) (TPF) induction chemotherapy followed by intensity-modulated radiotherapy (IMRT) concurrent with high-dose cisplatin in Epstein-Barr virus -related locally advanced undifferentiated nasopharyngeal cancer. Results: Thirty patients received three TPF cycles (median). Induction was well tolerated; the main toxicity was neutropenia (33%, grade 3-4). During chemoradiotherapy, neutropenia (40%) and mucositis (43%) were the most frequent grade 3-4 adverse events. Mean dose of IMRT was 68.8 Gy. Worst late toxicity was xerostomia. Complete response rate was 93%. At 35 months, two patients had locoregional recurrence, three had distant metastases, and one had both. Three-year progression-free survival and overall survival were 79% [95% confidence interval (CI) 64% to 94%] and 87% (95% CI 74%-to 100%), respectively.
introduction Nasopharyngeal carcinoma (NPC) is a curable disease and is generally considered a more radio and chemosensitive tumor than other head and neck squamous cell carcinomas. Based on these features, it is logical to optimize already proven curative treatments to improve both locoregional (LR) and distant disease control. A good LR control can be achieved by high-precision intensity-modulated radiotherapy (IMRT) and concomitant chemotherapy. The use of IMRT improves the distribution of the radiation dose, with potentially better efficacy and less toxic effects, particularly xerostomia, with respect to conventional radiotherapy [1] [2] [3] [4] . Distant metastases control remains a challenge, especially in undifferentiated and advanced-stage NPC, even if the adjunct of chemotherapy was effective in reducing metastatization when carried out before radiotherapy or concurrently with it [5] .
Two meta-analyses of randomized trials found a small but significant survival benefit when chemotherapy was combined with radiotherapy compared with radiotherapy alone in patients with locally advanced disease [5, 6] . The absolute 5-year survival benefit was 6% and 4%, respectively. Based on these findings, chemotherapy given concurrently with radiotherapy is now considered the standard of treatment in patients with stage III and IV (A-B) disease [7] .
Due to NPC chemosensitivity, neoadjuvant chemotherapy has also been extensively studied. However, randomized phase III studies of induction chemotherapy followed by radiotherapy failed to show improved overall survival (OS) rates compared with radiotherapy alone [8] [9] [10] [11] [12] . Nevertheless, a beneficial effect on disease-free survival in some of these trials or on specific subgroups suggests that integration of induction chemotherapy in multimodality treatment may deserve further attention [10, 13, 14] .
The induction regimen of docetaxel, cisplatin and 5-fluorouracil (5-FU) (TPF) with or without leucovorin has significant activity in patients with locally advanced squamous cell carcinoma of the head and neck [15] , while two pivotal phase III studies confirmed that TPF-based induction is associated with better OS and progression-free survival (PFS) compared with cisplatin plus 5-FU [16, 17] .
In order to transfer these results to locally advanced EpsteinBarr virus (EBV)-related NPC, we evaluated the feasibility, safety and efficacy of TPF induction chemotherapy followed by IMRT concurrent with chemotherapy in a homogeneous population treated at our Institution. for 96 h. Prophylactic ciprofloxacin 500 mg/day was given from day 5 to day 15. Primary prophylaxis with granulocyte-colony stimulating factor (G-CSF) was not given. Following induction chemotherapy, patients received concurrent chemoradiotherapy, which consisted of cisplatin 100 mg/m 2 every 21 days during standard full-dose radiotherapy. During concurrent chemoradiotherapy, patients were assessed and managed for treatmentrelated toxicity once a week. Chemotherapy delay or dose modification followed institutional procedures. The chemotherapy cycle was delayed until recovery of toxicity in case of: a neutrophil count of <1.5 · 10 9 /l or platelets <100 · 10 9 /l; gastrointestinal toxicity grade ‡3 or any toxicity (except from alopecia) grade ‡2; and 24-h creatinine clearance <60 ml/min. If a 24-h creatinine clearance of <60 ml/min persisted for >1 week during the concurrent treatment phase, the cisplatin dose was reduced by 25% (creatinine clearance 50-60 ml/min) or substituted with carboplatin area under the curve (AUC) of 6 (creatinine clearance <50 ml/min); during the induction phase, after 1 week of creatinine clearance <60 ml/min, cisplatin was substituted with carboplatin AUC 5.
methods and materials
At the first episode of febrile neutropenia or documented infection, G-CSF was added to all subsequent treatment cycles. If there was a second episode, the patient remained on ciprofloxacin and G-CSF, and additionally, during the subsequent cycles, docetaxel dose was reduced from 75 to 60 mg/m 2 in the induction phase, while cisplatin dose was reduced by 25% in the concurrent phase. In case of gastrointestinal toxicity grade ‡3, 5-FU dose at the following cycle was reduced to 600 mg/m 2 /day. During chemoradiotherapy, mucositis/stomatitis grade ‡3 caused a delay in chemotherapy administration of 1 week and a dose reduction in the following cycle of 25%. Optimal supportive care during whole treatment was adopted. Radiation therapy planning procedures were usually carried out shortly after the completion of induction chemotherapy and radiation treatment started within 3-4 weeks from the last cycle of chemotherapy. Radiation therapy was delivered using the extended whole-field IMRT technique with seven gantry positions. During this study period, two different radiation therapy fractionation schedules were used: (i) 'sequential' (SEQ) IMRT based on the shrinking-field approach at the total dose to the high-risk planning target volumes (PTV) of 66-70 Gy/2 Gy-fraction/33-35 fractions and (ii) 'simultaneous integrated boost' (SIB) IMRT (SIB/SEQ) moderately accelerated at the total dose to the high-dose PTV of 70 Gy/2.12 Gyfraction/33 fractions. [18] . Adverse events were graded and/or reviewed according to the criteria of the National Cancer Institute Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 [19] .
Follow-up consisted of physical examination and imaging with MRI every 3 months for the first 2 years, then every 6 months for another year, then annually. Response according to RECIST criteria was assessed after induction chemotherapy, 3 and 6 months after the end of treatment.
Plasma EBV DNA was measured with a real-time quantitative PCR system that amplifies a region of the gene coding the EBNA-1 protein of the EBV genome. Results were expressed as the number of copies of EBV DNA genome per millimeter of serum. EBER was detected in primary tumor biopsies by in situ hybridization on paraffin-embedded tissue sections using a fluorescein-conjugated oligonucleotide probe for EBER.
outcome analysis OS was defined as the time from the start of chemotherapy until the date of death from any cause, and PFS was measured from the date of the first chemotherapy cycle to the date of progressive disease or death from any cause in the absence of progression. OS and PFS curves were estimated with the Kaplan-Meier method. Data on safety were shown in terms of adverse events and grade.
results baseline characteristics
Between October 2004 and August 2008, 47 patients with locally advanced NPC were treated at our Institution; 30 patients (21 males; mean age 46.7 6 11.2 years) who met selection criteria were considered for analysis, while 15 patients were excluded due to differences in radiotherapy technique and 2 due to a keratinizing histology. Demographic and disease characteristics are shown in Table 1 .
Most patients had significant nodal involvement; 29 patients (97%) had N2 or N3 disease. Plasmatic EBV DNA was positive in 17 out of 25 tested patients, with a median EBV DNA level of 5538 copies/ml (range: 481-76 400 copies/ml). EBER was expressed in five patients whose baseline serum EBV DNA was not available and in eight patients with negative plasmatic EBV DNA.
induction chemotherapy
Patients received between one and four induction cycles (median three cycles). In total, 18/30 (60%) received at least original article Annals of Oncology three induction cycles. Five patients switched from cisplatin to carboplatin, while dose intensity of all drugs administered was at least 95% of the defined dose.
concurrent chemoradiotherapy
Three cycles of platinum compounds were administered to 15 (50%) patients (6 of whom at full dosage) and two cycles to the remaining patients. The dose intensity of platinum compounds administered concurrently with radiotherapy was 77%; there was no difference in concurrent dose intensity between patients having received one to two cycles or three to four cycles of induction chemotherapy. During concurrent chemotherapy, 5 patients out of 30 switched to full-dose concomitant carboplatin; among them, 4 have received more than two induction cycles. Carboplatin substituted cisplatin in 8 (11%) out of 75 concomitantly administered cycles.
Radiotherapy was given as IMRT in all patients. The total dose to high-risk PTV was 66 Gy in 9 patients (30%) and 70 Gy in 21 patients (70%). The mean dose was 68.8 Gy. The compliance with radiotherapy was optimal in the vast majority of patients receiving planned treatment without breaks due to acute effects. The overall median treatment time was 52 days (interquartile range 50-54 days).
safety Severe (grade 3 or 4) adverse events observed during the induction and during the concomitant phase are reported in Table 2 .
A nasogastric tube was necessary for pain dysphagia (median time 36 days, range 10-68 days) in eight patients. During the concomitant phase, causes of reduction in platinum dose intensity were mucositis (13 patients, 43%), neutropenia (12 patients, 40%), and renal impairment (5 patients, 17%). There were no serious adverse events leading to treatment discontinuation.
Observed toxic effects at 3 and 12 months after the end of treatment are depicted in Table 3 .
As compared with patients receiving more than two TPF cycles, those receiving one or two induction cycles experienced significantly less G3-G4 neutropenia (17% versus 56%, P value at Fisher's exact test = 0.038) and less G1-G2 renal toxicity in concomitant phase, although statistical significance was not reached (17% versus 39%, P = 0.187). No clinically relevant differences were encountered between the two groups in the incidence of mucositis experienced during chemoradiotherapy (42% versus 44%, P = 0.590).
response and survival
All patients showed a partial response after induction chemotherapy. There was a high rate of complete response after completing treatment (28/30; 93% of patients), as assessed at the first MRI carried out at 3 months and confirmed at the following MRI 3 months later. At this time point, there was no LR progression or distant metastasis in any patient.
One week after completing treatment, no patients had positive plasmatic EBV DNA values.
At a median follow-up of 35 months (interquartile range 24-48 months), a complete response was still evident in 24 (80%) patients, while 6 (20%) experienced recurrence of disease. Of these six patients, two had LR failure (one on T and one on T + N), three had distant metastases (M) and one patient had both (T + M). OS and PFS curves are shown in Figure 1 . Estimated 3-year OS was 87% [95% confidence interval (CI) 74%-to 100%] and PFS was 79% (95% CI 64%-to 94%). When interpreting the results of our study, it should be noted that this was a small noncomparative study, carried out in a non-endemic setting of disease. However, our study is the first to evaluate TPF induction chemotherapy as a part of a sequential regimen including IMRT concurrent with highdose cisplatin chemotherapy in patients with locally advanced NPC and provides valuable information regarding the feasibility of this treatment strategy. Our results suggest that this treatment schedule has an acceptable toxicity profile, allows for full radiotherapy delivery and has a promising activity. Noteworthy, the induction TPF used in this study allowed a reduction in the doses of 5-FU when compared with the TPF developed in Europe [17] .
All the patients completed the radiation treatment at the planned dose without treatment interruptions due to toxicity, while chemotherapy dose reduction was required, in particular during the concomitant phase, due to mucositis, neutropenia and renal impairment. Nevertheless, the dose intensity of platinum concurrent to radiotherapy was 77%, and all patients received at least two cycles of concomitant chemotherapy. These data compare favorably with the percentage of patients receiving at least two cycles of cisplatin concurrent to radiation in the two large postoperative studies (range: 79%-83%) [20] , although the doses of concomitant radiation were lower than in the current study, considering the postoperative setting. Interestingly, only 86% of the patients received at least two cycles of concomitant cisplatin in the NPC Intergroup study of concurrent high-dose radiotherapy followed by adjuvant chemotherapy [21] . In the TREMPLIN study, an organ preservation trial, 83% of patients randomized to cisplatin received at least two concomitant cycles of this agent [22] . Our data suggest that induction TPF with a modest reduction in FU could allow for an optimal cisplatin delivery in the concomitant phase and that optimal supportive care is vital for the correct application of this treatment strategy.
Neutropenia and increase in creatinine value was more frequent in patients receiving more than two cycles of induction chemotherapy, without affecting the dose intensity of concomitant platinum. Nevertheless, a switch to carboplatin chemotherapy was observed more frequently in patients receiving a high number of induction cycles. Mucositis was the most severe toxicity observed in the concurrent treatment phase, reaching grade 3 in 43% of patients; it was also the most reported adverse event in all phase II studies employing this integrated treatment option with induction chemotherapy followed by concurrent radiochemotherapy (G3-G4 mucositis ranging from 24% to 65% of patients) [14, [23] [24] [25] [26] [27] [28] [29] .
It should be noted that sequential treatment adopted in this study is costly, and its aggressive nature could be associated with significant toxicity and unknown late morbidity. However, our study and those of Oh et al. [27] , Chan et al. [24] and Rischin et al. [28] showed favorable late toxicity profiles and the absence of deaths reported up to 1 year after the end of treatment. Xerostomia was the most prominent adverse event (>50% of patients with grade 2 xerostomia 1 year after the end of treatment), but it generally decreased over time. In Figure 1 . Kaplan-Meier overall survival (OS) and progression-free survival (PFS) curves.
original article Annals of Oncology our study, this late effect was somewhat higher compared with other IMRT studies [30] [31] [32] , probably because our study population was composed of patients with stage III/IV disease with a high frequency of parapharyngeal extensions and large upper bilateral neck nodes. Under these conditions, it is not always possible to spare the parotid glands during IMRT.
The clinical outcomes reported in our IMRT series is comparable to that observed in contemporary studies using IMRT for locally advanced NPC [30, 31, 33] . However, we adopted a conventional or moderately accelerated fractionation, while, on the other hand, the majority of series published to date used some form of strong acceleration or dose escalation beyond 70, and very rarely induction chemotherapy. Therefore, our data could suggest that in presence of optimized induction chemotherapy IMRT total dose can be conventional. Moreover, our approach is associated with an acceptable acute toxicity level and could avoid the potential risk of increase in severe late toxicity [32] .
A large proportion of the patients in our study had a complete response 6 months after treatment (93%) and maintained it for the duration of the follow-up examined (80% of patients at last follow-up). Similarly high rates of complete response have been reported in recent small noncomparative studies with two to three cycles of platinum-based induction chemotherapy followed by chemoradiotherapy (79%-100%) [23, 24, 27, 28, 34, 35] .
Previous studies showed that cisplatin-based induction polychemotherapy to radiotherapy (without concurrent chemotherapy) significantly improves the overall response rate and event-free survival versus radiotherapy alone without improvement in OS [10, 12] . The lack of OS benefit has been attributed to the high rate of treatment-related deaths [8] or to suboptimal drug combinations or insufficient efficacy of radiotherapy due to the lack of concurrent chemotherapy.
Our low rates of LR failures are in line with the results reported in previous induction plus concomitant chemoradiotherapy studies [24, 27, 28] . It has been proposed that sequential chemotherapy, followed by chemoradiotherapy, could also lead to improvements in systemic control by maximizing micrometastasis eradication. Having observed only 4/30 distant relapses, our data appear to support such hypothesis.
Estimated 3-year OS in our analysis reached 87%; when examining 3-year OS in previous quoted phase II studies, treatment with induction and concurrent chemoradiotherapy ranged from 71% to 94%. Noteworthy, the current patient population had some unfavorable characteristics, such as a more advanced nodal disease and a serum pretreatment EBV DNA value higher than 1500 copies/ml in 10 out of 17 positive patients [36] .
Data in support of efficacy of induction triple drug taxanebased polychemotherapy in advanced NPC are still lacking; we believe that this approach, which is often unfeasible in the adjuvant setting, could represent an interesting therapeutic strategy to improve clinical outcomes. Our report shows that induction TPF is safe and apparently does not compromise optimal current IMRT concomitantly with full-dose cisplatin. 
